Eleven Generic Drugs Pass Consistency Evaluation Involving Kelun, Qilu, and Luoxin

Jan 29, 2021 11:06 CST Updated 11:06

Kelun

Innovative Pharmaceutical R&D Company

Qilu Pharmaceutical

Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer

Haisco

New Drug Research and Development, Production, and Sales

Salubris

Pharmaceutical Product R&D Developer

On January 29, the National Medical Products Administration (NMPA) released the notice regarding drug approval documents available for collection in January 2021. Among them, Shandong Weigao’s Compound Amino Acid (15) Peritoneal Dialysis Solution was approved for market launch on January 27. Additionally, 11 generic drugs passed the consistency evaluation, including Sichuan Kelun’s Compound Amino Acid (15AA-I)/Glucose and Electrolyte Injection and Omega-3 Fish Oil Medium/Long-Chain Triglyceride Emulsion for Injection; Zhuhai United Laboratories’ (Zhongshan Branch) Tenofovir Disoproxil Fumarate Tablets; Qilu Pharmaceutical’s Metformin and Vildagliptin Tablets; Haisco’s Ticagrelor Tablets; Luoxin Pharmaceutical’s Tadalafil Tablets; Salubris’ Rivaroxaban Tablets; and Nanjing Simcere Dongyuan Pharmaceutical’s Celecoxib Capsules, among others.

As shown in the figure below:

*Disclaimer: This article was written by an author contributing to Sina Medical News. The views expressed are solely those of the author and do not represent the position of Sina Medical News.